It green morning with biotechs taking part in the early rally and showing perhaps some minor strength but nothing earth shattering. Again it was a relatively quiet day on the news front, so I will do a couple of quick hitters today. 1. PCYC got another positive sell side report. I think we are clearly […]
October 3- EOD
Outside of a weak day in the macro which appears mainly related to macro issues, there does not seem to be a ton of news. Biotechs were obviously weak with the broader market but there was some green sprinkled in but they were few and far between. I will highlight a couple of companies but […]
October 2- EOD
Some macro weakness today but biotechs seemed to hold up fairly well. While most were red, it did not seem to be overdone to the downside. Plus, there were some pockets of green. All in all, not a great day to be in biotechs but it could have been worse given the broader market. The […]
October 1- EOD
It was a fairly busy day today in biotech land the sentiment certainly appears more positive. They participated in the market rally even though most were not big losers in the recent macro selling. This is certainly positive going forward. I want to focus on the MRK news as it touches on a lot of […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
September 27- EOD
Not a particularly news rich day but the sector seemed to continue its momentum from yesterday and seemed to outperform the general market with a lot of green on a red day. 1. Well, it looks like JNJ is tossing another wrench in ECYT trials with more doxil supply problems. ECYT noted that they have […]
September 26-EOD
It was an interesting news day and biotechs even participated in the market strength today, which has not happened in a little while. I would not call the biotech action strong from a relative performance sense but it is encouraging to see them at least perform in line with the broader market. 1. Lilly(LLY) announced […]
September 25- EOD
A very interesting and odd day in the market today. Overall the market continued its weakness and biotechs were generally down. The market came back and it seemed to turn into a chop fest. I suspected that the CLVS news would have had a more negative impact on biotech sentiment but there did not seem […]
September 23rd EOD
It was a weak day in biotech (although it seemed to recover a little in the afternoon) and some of the biggest biotech bulls are turning cautious. Mike King of JMP was out with a note this morning talking about taking money off the table. He is still a long term biotech bull but thinks […]
September 20- Daily Update – SRPT
Obviously the big news of the day was the failure of drisapersen in their phase III trial and what it means for etperlirsen and SRPT. While it is not clear if this was RNA related but biotechs were generally weak, although not dramatically so. Before diving into the drisapersen, I want to touch on a […]
September 19- EOD
It was a relatively quiet news day. I was not sure there would be much to write about and there is nothing really new or compelling. There are some quick hitters for today and hopefully we can get some more news going tomorrow and next week. 1. I wrote a response to the ARIA bear […]
September 18- EOD
It was Fed day today, so the market was very macro driven in terms of price action. The Bernank doubled down on easing, which was a good macro environment. That being said biotechs were more mixed. I am actually starting to look at biopharma as more QE will likely lead to yield chasing. There were […]
September 18- EOD
It was Fed day today, so the market was very macro driven in terms of price action. The Bernank doubled down on easing, which was a good macro environment. That being said biotechs were more mixed. I am actually starting to look at biopharma as more QE will likely lead to yield chasing. There were […]
September 18- EOD
It was Fed day today, so the market was very macro driven in terms of price action. The Bernank doubled down on easing, which was a good macro environment. That being said biotechs were more mixed. I am actually starting to look at biopharma as more QE will likely lead to yield chasing. There were […]
September 17- EOD
Not a lot of stock specific news but some interesting larger biotech developments. The market held up better than I thought given yesterday’s close and biotechs seemed like slight underperformers but not to the same degree as yesterday. That being said I think the CLVS news seemed to bring in some buyers, so they ended […]
September 16- EOD
It was a strong day in the market but a weak day in biotech. That being said I think there was a definite pattern in that the large caps and biopharmas seemed to outperform (although they were still weaker than the market) than the mid- and small- caps. In my mind, I read that as […]
September 16- EOD
It was a strong day in the market but a weak day in biotech. That being said I think there was a definite pattern in that the large caps and biopharmas seemed to outperform (although they were still weaker than the market) than the mid- and small- caps. In my mind, I read that as […]
September 16- EOD
It was a strong day in the market but a weak day in biotech. That being said I think there was a definite pattern in that the large caps and biopharmas seemed to outperform (although they were still weaker than the market) than the mid- and small- caps. In my mind, I read that as […]
